Abstract: Src family kinase(SFK)highly expresses in many types of cancers, broadly adjusting their malignant behaviors. Paclitaxel is a widely used chemical agent. However, because of constant resistance, the effect of paclitaxel has been greatly attenuated. The present review summaries the recent research progress of the structure and adjustment of SFK and the molecular mechanism of paclitaxel resistance, as well as the regulation of SFK on paclitaxel resistance, in order to provide new references and evidences upon the paclitaxel-based tumor therapy.